As of January 15, 2025, third line (3L) data showed median overall survival (OS) of 16.9 months for the 22 NSCLC patients who received at least one dose of THIO (the intent-to-treat population ...
In summary, MAIA Biotechnology’s recent updates regarding its Phase 2 THIO-101 trial demonstrate the company’s commitment to communicating significant developments in its oncology research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback